MANIKKAM SUTHANTHIRAN, MD
Osteopathic Medicine at 68 St, New York, NY
License number
New York 133562
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
525 E 68Th St, New York, NY 10021
Phone
(212) 746-4430
(212) 746-8091 (Fax)
(212) 746-0373
(212) 746-7481 (Fax)
(212) 746-8091 (Fax)
(212) 746-0373
(212) 746-7481 (Fax)
Personal information
See more information about MANIKKAM SUTHANTHIRAN at radaris.comName
Address
Phone
6 Uxbridge Rd, Scarsdale, NY 10583
Scarsdale, NY
6 Uxbridge Rd, Scarsdale, NY 10583
Organization information
See more information about MANIKKAM SUTHANTHIRAN at bizstanding.comManikkam Suthanthiran MD,MBBS,BS
505 E 70 St, New York, NY 10021
Industry:
Internist
Phone:
(212) 746-4430 (Phone)
Manikkam Suthanthiran
Cornell Unvi Medical College - Manikkam Suthanthiran MD
515 E 71 St #829, New York, NY 10021
Categories:
Colleges & Universities, Medical Schools
Phone:
(212) 746-4430 (Phone)
Professional information
Dr. Manikkam Suthanthiran - MD (Doctor of Medicine)
Hospitals:
Cornell University Medical Center
525 E 68Th St, New York 10065
Cornell University Medical Center
525 E 68Th St, New York 10065
525 E 68Th St, New York 10065
Cornell University Medical Center
525 E 68Th St, New York 10065
Education:
Medical Schools
Harvard Medical School
Harvard Medical School
Methods Of Evaluating Transplant Rejection
US Patent:
6187534, Feb 13, 2001
Filed:
Sep 24, 1997
Appl. No.:
8/937063
Inventors:
Terry B. Strom - Brookline MA
Lauro Vasconcellos - Brookline MA
Manikkam Suthanthiran - New York NY
Lauro Vasconcellos - Brookline MA
Manikkam Suthanthiran - New York NY
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
Beth Israel Deaconess Medical Center - Boston MA
Beth Israel Deaconess Medical Center - Boston MA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of two out of three immune activation marker genes perforin, granzyme B and Fas ligand, in a tissue biopsy or peripheral blood mononuclear cell sample, particularly using reverse transcription polymerase chain reaction; methods of assessing antirejection therapy; and kits for use in evaluating transplant rejection.